Verdicts genuinely change. Free email alert the moment BIB's does — no target price to set, unlike "Alert" above.
Whether this fund clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
ProShares Ultra Nasdaq Biotechnology ETF · ProShares Trust
267 holdings · as of 2026-05-31 (4.4 months ago) The fund may have traded since. SEC Form N-PORT is filed quarterly and lags the period it covers, so these are the most recent holdings on file, not the fund’s holdings today.
NON-COMPLIANT At least 12.75% of portfolio weight is in non-compliant holdings — already over the 5% threshold, so the verdict is settled whatever the unmatched 45% turns out to be. Matching more holdings can only raise this share, never lower it.
267 holdings, 162 matched (52% of weight). Portfolio as of 2026-05-31, filed 2026-07-28. Source: SEC Form N-PORT.
6.17% of this portfolio’s income is non-permissible — weighted across holdings, computed over 39% of portfolio weight (119 of 267 holdings). The common approach purifies that proportion of income received — dividends — not of the position’s value. We report the ratio; what to do with it is a question for your own scholar.
Portfolio shares are withheld: coverage is below the floor needed to state one. The holdings themselves are below, because the names are evidence you can check.
| Holding | Status | Weight | Every methodology, and the debt ratio behind it |
|---|---|---|---|
| N/A | UNSCREENED | 7.35% | no in-house ratios for this holding |
| ProShares GENIUS Money Market ETF | UNSCREENED | 6.80% | no in-house ratios for this holding |
| GILD Gilead Sciences, Inc. | COMPLIANT | 4.66% | AAOIFI14.4% Usmani53.2% Dow Jones Islamic18.6% S&P Shariah21.4% MSCI Islamic53.2% MSCI Islamic M-Series21.4% FTSE Shariah53.2% |
| VRTX Vertex Pharmaceuticals, Inc. | COMPLIANT | 4.65% | AAOIFI1.6% Usmani7.2% Dow Jones Islamic1.7% S&P Shariah1.7% MSCI Islamic7.2% MSCI Islamic M-Series1.7% FTSE Shariah0.0% |
| AMGN Amgen, Inc. | COMPLIANT | 4.48% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| N/A | UNSCREENED | 3.94% | no in-house ratios for this holding |
| N/A | UNSCREENED | 3.26% | no in-house ratios for this holding |
| REGN Regeneron Pharmaceuticals, Inc. | COMPLIANT | 3.21% | AAOIFI2.4% Usmani6.5% Dow Jones Islamic3.0% S&P Shariah2.7% MSCI Islamic4.8% MSCI Islamic M-Series2.7% FTSE Shariah4.8% |
| N/A | UNSCREENED | 2.62% | no in-house ratios for this holding |
| N/A | UNSCREENED | 2.36% | no in-house ratios for this holding |
| ALNY Alnylam Pharmaceuticals, Inc. | COMPLIANT | 2.01% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| Revolution Medicines, Inc. | UNSCREENED | 1.57% | no in-house ratios for this holding |
| BIIB Biogen, Inc. | COMPLIANT | 1.44% | AAOIFI21.2% Usmani22.5% Dow Jones Islamic27.5% S&P Shariah24.3% MSCI Islamic22.5% MSCI Islamic M-Series24.3% FTSE Shariah21.3% |
| Repurchase Agreement | UNSCREENED | 1.28% | no in-house ratios for this holding |
| ILMN Illumina, Inc. | COMPLIANT | 1.25% | AAOIFI1.6% Usmani8.1% Dow Jones Islamic2.7% S&P Shariah2.7% MSCI Islamic8.1% MSCI Islamic M-Series2.7% FTSE Shariah0.0% |
| UTHR United Therapeutics Corp. | NON_COMPLIANT | 1.22% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| RPRX Royalty Pharma plc | NON_COMPLIANT | 1.20% | AAOIFI24.4% Usmani45.2% Dow Jones Islamic60.3% S&P Shariah67.3% MSCI Islamic45.2% MSCI Islamic M-Series67.3% FTSE Shariah45.2% |
| ARGX Argenx SE | COMPLIANT | 1.19% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| N/A | UNSCREENED | 1.18% | no in-house ratios for this holding |
| Insmed, Inc. | UNSCREENED | 1.16% | no in-house ratios for this holding |
| Roivant Sciences Ltd. | UNSCREENED | 1.08% | no in-house ratios for this holding |
| INCY Incyte Corp. | COMPLIANT | 0.97% | AAOIFI0.1% Usmani0.7% Dow Jones Islamic0.1% S&P Shariah0.1% MSCI Islamic0.3% MSCI Islamic M-Series0.1% FTSE Shariah0.0% |
| VTRS Viatris, Inc. | NON_COMPLIANT | 0.94% | AAOIFI65.8% Usmani38.9% Dow Jones Islamic100.2% S&P Shariah105.1% MSCI Islamic38.9% MSCI Islamic M-Series105.1% FTSE Shariah38.1% |
| MRNA Moderna, Inc. | NON_COMPLIANT | 0.94% | AAOIFI2.2% Usmani11.7% Dow Jones Islamic7.4% S&P Shariah5.1% MSCI Islamic11.4% MSCI Islamic M-Series5.1% FTSE Shariah5.4% |
| GH Guardant Health, Inc. | COMPLIANT | 0.85% | AAOIFI7.8% Usmani88.7% Dow Jones Islamic17.9% S&P Shariah23.1% MSCI Islamic88.7% MSCI Islamic M-Series23.1% FTSE Shariah78.6% |
| INVESCO GOVT AND AGCY LEX | UNSCREENED | 0.81% | no in-house ratios for this holding |
| Repurchase Agreement | UNSCREENED | 0.81% | no in-house ratios for this holding |
| NBIX Neurocrine Biosciences, Inc. | COMPLIANT | 0.80% | AAOIFI2.9% Usmani8.6% Dow Jones Islamic3.4% S&P Shariah3.5% MSCI Islamic8.6% MSCI Islamic M-Series3.5% FTSE Shariah0.0% |
| JAZZ Jazz Pharmaceuticals plc | COMPLIANT | 0.73% | AAOIFI31.0% Usmani39.7% Dow Jones Islamic44.2% S&P Shariah48.5% MSCI Islamic39.7% MSCI Islamic M-Series48.5% FTSE Shariah39.3% |
| ASND Ascendis Pharma A/S | COMPLIANT | 0.69% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| Summit Therapeutics, Inc. | UNSCREENED | 0.68% | no in-house ratios for this holding |
| EXEL Exelixis, Inc. | COMPLIANT | 0.66% | AAOIFI1.2% Usmani6.7% Dow Jones Islamic1.5% S&P Shariah1.7% MSCI Islamic6.7% MSCI Islamic M-Series1.7% FTSE Shariah0.0% |
| BBIO Bridgebio Pharma, Inc. | COMPLIANT | 0.64% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| MEDP Medpace Holdings, Inc. | COMPLIANT | 0.64% | AAOIFIpass Usmani— Dow Jones Islamicpass S&P Shariahpass MSCI Islamicfail MSCI Islamic M-Seriespass FTSE Shariah— |
| IONS Ionis Pharmaceuticals, Inc. | NON_COMPLIANT | 0.63% | AAOIFI21.0% Usmani67.5% Dow Jones Islamic23.0% S&P Shariah25.1% MSCI Islamic67.5% MSCI Islamic M-Series25.1% FTSE Shariah58.8% |
| Repurchase Agreement | UNSCREENED | 0.61% | no in-house ratios for this holding |
| AXSM Axsome Therapeutics, Inc. | COMPLIANT | 0.60% | AAOIFI1.9% Usmani29.5% Dow Jones Islamic2.9% S&P Shariah3.5% MSCI Islamic27.6% MSCI Islamic M-Series3.5% FTSE Shariah24.7% |
| MDGL Madrigal Pharmaceuticals, Inc. | COMPLIANT | 0.57% | AAOIFI2.8% Usmani27.9% Dow Jones Islamic3.8% S&P Shariah4.6% MSCI Islamic27.9% MSCI Islamic M-Series4.6% FTSE Shariah27.4% |
| BMRN BioMarin Pharmaceutical, Inc. | NON_COMPLIANT | 0.55% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| 22UA.DE BioNTech SE | NON_COMPLIANT | 0.55% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariahfail MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| ARWR Arrowhead Pharmaceuticals, Inc. | COMPLIANT | 0.55% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| SNY Sanofi SA | COMPLIANT | 0.54% | AAOIFI20.8% Usmani14.7% Dow Jones Islamic38.1% S&P Shariah38.6% MSCI Islamic14.7% MSCI Islamic M-Series38.6% FTSE Shariah14.7% |
| Praxis Precision Medicines, Inc. | UNSCREENED | 0.49% | no in-house ratios for this holding |
| CYTK Cytokinetics, Inc. | NON_COMPLIANT | 0.47% | AAOIFI3.9% Usmani20.7% Dow Jones Islamic5.9% S&P Shariah6.2% MSCI Islamic20.7% MSCI Islamic M-Series6.2% FTSE Shariah14.3% |
| ONC BeOne Medicines Ltd. | COMPLIANT | 0.46% | AAOIFI2.8% Usmani12.5% Dow Jones Islamic0.3% S&P Shariah0.3% MSCI Islamic12.5% MSCI Islamic M-Series0.3% FTSE Shariah11.7% |
| KRYS Krystal Biotech, Inc. | NON_COMPLIANT | 0.45% | AAOIFI0.1% Usmani0.6% Dow Jones Islamic0.1% S&P Shariah0.2% MSCI Islamic0.6% MSCI Islamic M-Series0.2% FTSE Shariah0.0% |
| Repurchase Agreement | UNSCREENED | 0.44% | no in-house ratios for this holding |
| TEM Tempus AI, Inc. | COMPLIANT | 0.44% | AAOIFI0.7% Usmani3.5% Dow Jones Islamic0.8% S&P Shariahpass MSCI Islamic3.5% MSCI Islamic M-Seriespass FTSE Shariah0.0% |
| Abivax SA | UNSCREENED | 0.41% | no in-house ratios for this holding |
| Nuvalent, Inc. | UNSCREENED | 0.41% | no in-house ratios for this holding |
| HALO Halozyme Therapeutics, Inc. | COMPLIANT | 0.39% | AAOIFI17.2% Usmani83.3% Dow Jones Islamic27.4% S&P Shariah30.4% MSCI Islamic83.3% MSCI Islamic M-Series30.4% FTSE Shariah83.3% |
| ImmunityBio, Inc. | UNSCREENED | 0.39% | no in-house ratios for this holding |
| Vaxcyte, Inc. | UNSCREENED | 0.37% | no in-house ratios for this holding |
| ALKS Alkermes plc | COMPLIANT | 0.35% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| Immunovant, Inc. | UNSCREENED | 0.34% | no in-house ratios for this holding |
| KYMR Kymera Therapeutics, Inc. | NON_COMPLIANT | 0.33% | AAOIFI0.8% Usmani4.8% Dow Jones Islamic1.7% S&P Shariah2.1% MSCI Islamic4.6% MSCI Islamic M-Series2.1% FTSE Shariah0.0% |
| PTGX Protagonist Therapeutics, Inc. | NON_COMPLIANT | 0.32% | AAOIFI0.1% Usmani1.0% Dow Jones Islamic0.2% S&P Shariah0.3% MSCI Islamic1.0% MSCI Islamic M-Series0.3% FTSE Shariah0.0% |
| MIRM Mirum Pharmaceuticals, Inc. | COMPLIANT | 0.31% | AAOIFI11.6% Usmani73.0% Dow Jones Islamic20.3% S&P Shariah25.7% MSCI Islamic73.0% MSCI Islamic M-Series25.7% FTSE Shariah71.8% |
| PTCT PTC Therapeutics, Inc. | NON_COMPLIANT | 0.31% | AAOIFI11.9% Usmani21.4% Dow Jones Islamic16.9% S&P Shariah20.0% MSCI Islamic21.2% MSCI Islamic M-Series20.0% FTSE Shariah18.2% |
| RYTM Rhythm Pharmaceuticals, Inc. | NON_COMPLIANT | 0.30% | AAOIFI1.6% Usmani25.1% Dow Jones Islamic2.0% S&P Shariah2.5% MSCI Islamic25.1% MSCI Islamic M-Series2.5% FTSE Shariah24.3% |
| Spyre Therapeutics, Inc. | UNSCREENED | 0.29% | no in-house ratios for this holding |
| Cogent Biosciences, Inc. | UNSCREENED | 0.28% | no in-house ratios for this holding |
| CRSP CRISPR Therapeutics AG | NON_COMPLIANT | 0.27% | AAOIFI15.5% Usmani29.6% Dow Jones Islamic17.0% S&P Shariah16.8% MSCI Islamic29.6% MSCI Islamic M-Series16.8% FTSE Shariah22.1% |
| CG oncology, Inc. | UNSCREENED | 0.26% | no in-house ratios for this holding |
| Scholar Rock Holding Corp. | UNSCREENED | 0.25% | no in-house ratios for this holding |
| Centessa Pharmaceuticals plc | UNSCREENED | 0.24% | no in-house ratios for this holding |
| CAI Caris Life Sciences, Inc. | COMPLIANT | 0.24% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| LGND Ligand Pharmaceuticals, Inc. | COMPLIANT | 0.23% | AAOIFI19.7% Usmani51.8% Dow Jones Islamic34.1% S&P Shariah42.6% MSCI Islamic51.8% MSCI Islamic M-Series42.6% FTSE Shariah51.5% |
| Xenon Pharmaceuticals, Inc. | UNSCREENED | 0.23% | no in-house ratios for this holding |
| Apogee Therapeutics, Inc. | UNSCREENED | 0.23% | no in-house ratios for this holding |
| INDV Indivior Pharmaceuticals, Inc. | COMPLIANT | 0.23% | AAOIFI12.3% Usmani41.3% Dow Jones Islamic17.8% S&P Shariah18.8% MSCI Islamic41.3% MSCI Islamic M-Series18.8% FTSE Shariah39.5% |
| TVTX Travere Therapeutics, Inc. | COMPLIANT | 0.22% | AAOIFI10.0% Usmani77.2% Dow Jones Islamic24.4% S&P Shariah32.6% MSCI Islamic77.2% MSCI Islamic M-Series32.6% FTSE Shariah75.4% |
| Amneal Pharmaceuticals, Inc. | UNSCREENED | 0.21% | no in-house ratios for this holding |
| TWST Twist Bioscience Corp. | COMPLIANT | 0.21% | AAOIFI1.1% Usmani13.9% Dow Jones Islamic3.2% S&P Shariah3.5% MSCI Islamic13.9% MSCI Islamic M-Series3.5% FTSE Shariah0.0% |
| Erasca, Inc. | UNSCREENED | 0.20% | no in-house ratios for this holding |
| Newamsterdam Pharma Co. NV | UNSCREENED | 0.19% | no in-house ratios for this holding |
| Crinetics Pharmaceuticals, Inc. | UNSCREENED | 0.19% | no in-house ratios for this holding |
| ACAD ACADIA Pharmaceuticals, Inc. | COMPLIANT | 0.19% | AAOIFIpass Usmanipass Dow Jones Islamicpass S&P Shariahpass MSCI Islamicpass MSCI Islamic M-Seriespass FTSE Shariahpass |
| VCYT Veracyte, Inc. | COMPLIANT | 0.18% | AAOIFI1.1% Usmani2.7% Dow Jones Islamic1.4% S&P Shariah1.6% MSCI Islamic2.7% MSCI Islamic M-Series1.6% FTSE Shariah0.0% |
| Edgewise Therapeutics, Inc. | UNSCREENED | 0.18% | no in-house ratios for this holding |
| BEAM Beam Therapeutics, Inc. | NON_COMPLIANT | 0.17% | AAOIFI8.2% Usmani17.8% Dow Jones Islamic10.4% S&P Shariah10.7% MSCI Islamic17.8% MSCI Islamic M-Series10.7% FTSE Shariah7.2% |
| Denali Therapeutics, Inc. | UNSCREENED | 0.17% | no in-house ratios for this holding |
| TXG 10X Genomics, Inc. | COMPLIANT | 0.17% | AAOIFI1.0% Usmani7.6% Dow Jones Islamic3.2% S&P Shariah2.5% MSCI Islamic7.6% MSCI Islamic M-Series2.5% FTSE Shariah0.0% |
| Dyne Therapeutics, Inc. | UNSCREENED | 0.16% | no in-house ratios for this holding |
| GPCR Structure Therapeutics, Inc. | NON_COMPLIANT | 0.15% | AAOIFI0.2% Usmani0.4% Dow Jones Islamic0.1% S&P Shariah0.1% MSCI Islamic0.4% MSCI Islamic M-Series0.1% FTSE Shariah0.0% |
| TNGX Tango Therapeutics, Inc. | NON_COMPLIANT | 0.15% | AAOIFI0.8% Usmani3.0% Dow Jones Islamic2.2% S&P Shariah2.5% MSCI Islamic3.0% MSCI Islamic M-Series2.5% FTSE Shariah0.0% |
| Oruka Therapeutics, Inc. | UNSCREENED | 0.14% | no in-house ratios for this holding |
| GRAL GRAIL, Inc. | NON_COMPLIANT | 0.14% | AAOIFI2.5% Usmani3.2% Dow Jones Islamic4.7% S&P Shariahfail MSCI Islamic3.2% MSCI Islamic M-Seriesfail FTSE Shariah0.0% |
| Alumis, Inc. | UNSCREENED | 0.14% | no in-house ratios for this holding |
| ARQT Arcutis Biotherapeutics, Inc. | COMPLIANT | 0.13% | AAOIFI3.8% Usmani23.4% Dow Jones Islamic5.0% S&P Shariah6.5% MSCI Islamic23.4% MSCI Islamic M-Series6.5% FTSE Shariah22.3% |
| Disc Medicine, Inc. | UNSCREENED | 0.13% | no in-house ratios for this holding |
| SUPN Supernus Pharmaceuticals, Inc. | COMPLIANT | 0.13% | AAOIFIpass Usmanipass Dow Jones Islamicpass S&P Shariahpass MSCI Islamicpass MSCI Islamic M-Seriespass FTSE Shariahpass |
| IDYA Ideaya Biosciences, Inc. | NON_COMPLIANT | 0.13% | AAOIFI0.8% Usmani2.2% Dow Jones Islamic1.2% S&P Shariah1.1% MSCI Islamic2.2% MSCI Islamic M-Series1.1% FTSE Shariah0.0% |
| Vera Therapeutics, Inc. | UNSCREENED | 0.13% | no in-house ratios for this holding |
| TARS Tarsus Pharmaceuticals, Inc. | COMPLIANT | 0.13% | AAOIFI2.3% Usmani14.5% Dow Jones Islamic3.8% S&P Shariah4.7% MSCI Islamic14.5% MSCI Islamic M-Series4.7% FTSE Shariah11.9% |
| Relay Therapeutics, Inc. | UNSCREENED | 0.13% | no in-house ratios for this holding |
| Mineralys Therapeutics, Inc. | UNSCREENED | 0.13% | no in-house ratios for this holding |
| Definium Therapeutics, Inc. | UNSCREENED | 0.12% | no in-house ratios for this holding |
| Enliven Therapeutics, Inc. | UNSCREENED | 0.12% | no in-house ratios for this holding |
| ADPT Adaptive Biotechnologies Corp. | COMPLIANT | 0.12% | AAOIFI2.0% Usmani11.8% Dow Jones Islamic3.9% S&P Shariah5.1% MSCI Islamic11.8% MSCI Islamic M-Series5.1% FTSE Shariah0.0% |
| RARE Ultragenyx Pharmaceutical, Inc. | NON_COMPLIANT | 0.12% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| LEGN Legend Biotech Corp. | COMPLIANT | 0.12% | AAOIFI8.8% Usmani18.4% Dow Jones Islamic2.9% S&P Shariah2.3% MSCI Islamic18.4% MSCI Islamic M-Series2.3% FTSE Shariah18.4% |
| Kodiak Sciences, Inc. | UNSCREENED | 0.11% | no in-house ratios for this holding |
| BioCryst Pharmaceuticals, Inc. | UNSCREENED | 0.11% | no in-house ratios for this holding |
| KNSA Kiniksa Pharmaceuticals International plc | COMPLIANT | 0.11% | AAOIFI0.2% Usmani1.1% Dow Jones Islamic0.3% S&P Shariah0.4% MSCI Islamic1.1% MSCI Islamic M-Series0.4% FTSE Shariah0.0% |
| AUPH Aurinia Pharmaceuticals, Inc. | COMPLIANT | 0.10% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| OCUL Ocular Therapeutix, Inc. | NON_COMPLIANT | 0.10% | AAOIFI0.3% Usmani1.0% Dow Jones Islamic0.4% S&P Shariah0.5% MSCI Islamic1.0% MSCI Islamic M-Series0.5% FTSE Shariah0.0% |
| NVCR Novocure Ltd. | NON_COMPLIANT | 0.10% | AAOIFI11.1% Usmani29.2% Dow Jones Islamic12.7% S&P Shariah12.9% MSCI Islamic29.2% MSCI Islamic M-Series12.9% FTSE Shariah24.5% |
| Pharvaris NV | UNSCREENED | 0.10% | no in-house ratios for this holding |
| Sionna Therapeutics, Inc. | UNSCREENED | 0.10% | no in-house ratios for this holding |
| ADMA ADMA Biologics, Inc. | COMPLIANT | 0.10% | AAOIFIpass Usmanipass Dow Jones Islamicpass S&P Shariahpass MSCI Islamicfail MSCI Islamic M-Seriespass FTSE Shariahpass |
| Rapport Therapeutics, Inc. | UNSCREENED | 0.09% | no in-house ratios for this holding |
| ZYME Zymeworks, Inc. | NON_COMPLIANT | 0.09% | AAOIFI1.0% Usmani4.0% Dow Jones Islamic1.2% S&P Shariah1.5% MSCI Islamic4.0% MSCI Islamic M-Series1.5% FTSE Shariah0.0% |
| RXRX Recursion Pharmaceuticals, Inc. | NON_COMPLIANT | 0.09% | AAOIFI3.4% Usmani5.5% Dow Jones Islamic7.3% S&P Shariah6.1% MSCI Islamic5.5% MSCI Islamic M-Series6.1% FTSE Shariah1.2% |
| Sarepta Therapeutics, Inc. | UNSCREENED | 0.09% | no in-house ratios for this holding |
| ABCL AbCellera Biologics, Inc. | NON_COMPLIANT | 0.09% | AAOIFI3.8% Usmani10.4% Dow Jones Islamic11.0% S&P Shariah11.0% MSCI Islamic10.4% MSCI Islamic M-Series11.0% FTSE Shariah0.0% |
| Harmony Biosciences Holdings, Inc. | UNSCREENED | 0.09% | no in-house ratios for this holding |
| NRIX Nurix Therapeutics, Inc. | NON_COMPLIANT | 0.09% | AAOIFI2.1% Usmani10.9% Dow Jones Islamic4.1% S&P Shariah5.0% MSCI Islamic10.9% MSCI Islamic M-Series5.0% FTSE Shariah0.0% |
| Trevi Therapeutics, Inc. | UNSCREENED | 0.09% | no in-house ratios for this holding |
| NVAX Novavax, Inc. | NON_COMPLIANT | 0.09% | AAOIFI17.3% Usmani31.1% Dow Jones Islamic21.2% S&P Shariah22.9% MSCI Islamic30.5% MSCI Islamic M-Series22.9% FTSE Shariah30.5% |
| TYRA Tyra Biosciences, Inc. | COMPLIANT | 0.09% | AAOIFI0.3% Usmani1.5% Dow Jones Islamic0.5% S&P Shariah0.6% MSCI Islamic1.5% MSCI Islamic M-Series0.6% FTSE Shariah0.0% |
| uniQure NV | UNSCREENED | 0.09% | no in-house ratios for this holding |
| STOK Stoke Therapeutics, Inc. | NON_COMPLIANT | 0.09% | AAOIFI0.1% Usmani0.7% Dow Jones Islamic0.2% S&P Shariah0.3% MSCI Islamic0.7% MSCI Islamic M-Series0.3% FTSE Shariah0.0% |
| ANIP ANI Pharmaceuticals, Inc. | NON_COMPLIANT | 0.09% | AAOIFI18.2% Usmani20.2% Dow Jones Islamic16.9% S&P Shariah17.9% MSCI Islamic20.2% MSCI Islamic M-Series17.9% FTSE Shariah20.2% |
| Syndax Pharmaceuticals, Inc. | UNSCREENED | 0.09% | no in-house ratios for this holding |
| AGIO Agios Pharmaceuticals, Inc. | NON_COMPLIANT | 0.09% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariahfail MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| GMAB.CO Genmab A/S | COMPLIANT | 0.09% | AAOIFIpass Usmanifail Dow Jones Islamicfail S&P Shariahpass MSCI Islamicfail MSCI Islamic M-Seriespass FTSE Shariahfail |
| VCEL Vericel Corp. | COMPLIANT | 0.08% | AAOIFI4.0% Usmani18.5% Dow Jones Islamic4.4% S&P Shariah4.4% MSCI Islamic18.4% MSCI Islamic M-Series4.4% FTSE Shariah0.0% |
| IOVA Iovance Biotherapeutics, Inc. | COMPLIANT | 0.08% | AAOIFI1.2% Usmani5.0% Dow Jones Islamic2.9% S&P Shariah2.4% MSCI Islamic5.0% MSCI Islamic M-Series2.4% FTSE Shariah0.0% |
| NTLA Intellia Therapeutics, Inc. | NON_COMPLIANT | 0.08% | AAOIFI4.1% Usmani8.6% Dow Jones Islamic5.1% S&P Shariah4.1% MSCI Islamic8.6% MSCI Islamic M-Series4.1% FTSE Shariah0.0% |
| ATAI AtaiBeckley, Inc. | NON_COMPLIANT | 0.08% | AAOIFI0.9% Usmani9.4% Dow Jones Islamic2.0% S&P Shariah2.5% MSCI Islamic9.4% MSCI Islamic M-Series2.5% FTSE Shariah8.7% |
| TSHA Taysha Gene Therapies, Inc. | NON_COMPLIANT | 0.08% | AAOIFI3.1% Usmani12.1% Dow Jones Islamic5.9% S&P Shariah7.4% MSCI Islamic12.0% MSCI Islamic M-Series7.4% FTSE Shariah10.5% |
| INVA Innoviva, Inc. | NON_COMPLIANT | 0.08% | AAOIFI17.5% Usmani15.8% Dow Jones Islamic19.8% S&P Shariah21.9% MSCI Islamic15.8% MSCI Islamic M-Series21.9% FTSE Shariah15.2% |
| Amylyx Pharmaceuticals, Inc. | UNSCREENED | 0.08% | no in-house ratios for this holding |
| AnaptysBio, Inc. | UNSCREENED | 0.08% | no in-house ratios for this holding |
| PGEN Precigen, Inc. | NON_COMPLIANT | 0.08% | AAOIFI3.9% Usmani57.7% Dow Jones Islamic9.9% S&P Shariah12.7% MSCI Islamic57.7% MSCI Islamic M-Series12.7% FTSE Shariah55.1% |
| Inhibrx Biosciences, Inc. | UNSCREENED | 0.08% | no in-house ratios for this holding |
| GLUE Monte Rosa Therapeutics, Inc. | NON_COMPLIANT | 0.08% | AAOIFI4.3% Usmani5.5% Dow Jones Islamic4.5% S&P Shariah5.9% MSCI Islamic5.5% MSCI Islamic M-Series5.9% FTSE Shariah0.0% |
| VIR Vir Biotechnology, Inc. | NON_COMPLIANT | 0.08% | AAOIFI6.1% Usmani7.7% Dow Jones Islamic8.6% S&P Shariah8.1% MSCI Islamic7.7% MSCI Islamic M-Series8.1% FTSE Shariah0.0% |
| GH Research plc | UNSCREENED | 0.07% | no in-house ratios for this holding |
| ARDX Ardelyx, Inc. | COMPLIANT | 0.07% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| FTRE Fortrea Holdings, Inc. | NON_COMPLIANT | 0.07% | AAOIFI66.4% Usmani41.2% Dow Jones Islamic92.8% S&P Shariah65.5% MSCI Islamic41.2% MSCI Islamic M-Series65.5% FTSE Shariah38.8% |
| MBX Biosciences, Inc. | UNSCREENED | 0.07% | no in-house ratios for this holding |
| Bicara Therapeutics, Inc. | UNSCREENED | 0.07% | no in-house ratios for this holding |
| KalVista Pharmaceuticals, Inc. | UNSCREENED | 0.07% | no in-house ratios for this holding |
| SEPN Septerna, Inc. | NON_COMPLIANT | 0.07% | AAOIFI1.3% Usmani4.0% Dow Jones Islamic2.4% S&P Shariahfail MSCI Islamic4.0% MSCI Islamic M-Seriesfail FTSE Shariah0.0% |
| URGN UroGen Pharma Ltd. | NON_COMPLIANT | 0.07% | AAOIFI8.9% Usmani77.6% Dow Jones Islamic21.2% S&P Shariah25.0% MSCI Islamic75.9% MSCI Islamic M-Series25.0% FTSE Shariah74.7% |
| HROW Harrow, Inc. | COMPLIANT | 0.07% | AAOIFI21.7% Usmani74.0% Dow Jones Islamic22.2% S&P Shariah29.2% MSCI Islamic74.0% MSCI Islamic M-Series29.2% FTSE Shariah72.0% |
| MAZE Maze Therapeutics, Inc. | COMPLIANT | 0.06% | AAOIFI4.2% Usmani11.4% Dow Jones Islamicfail S&P Shariahfail MSCI Islamic11.4% MSCI Islamic M-Seriesfail FTSE Shariah7.3% |
| IMCR Immunocore Holdings plc | NON_COMPLIANT | 0.06% | AAOIFI24.8% Usmani42.8% Dow Jones Islamic29.4% S&P Shariah24.5% MSCI Islamic42.8% MSCI Islamic M-Series24.5% FTSE Shariah39.2% |
| ArriVent Biopharma, Inc. | UNSCREENED | 0.06% | no in-house ratios for this holding |
| WVE WaVe Life Sciences Ltd. | NON_COMPLIANT | 0.06% | AAOIFI3.9% Usmani7.8% Dow Jones Islamic2.9% S&P Shariah3.6% MSCI Islamic7.8% MSCI Islamic M-Series3.6% FTSE Shariah0.0% |
| Compass Pathways plc | UNSCREENED | 0.06% | no in-house ratios for this holding |
| PSNL Personalis, Inc. | NON_COMPLIANT | 0.06% | AAOIFI2.0% Usmani11.9% Dow Jones Islamic5.7% S&P Shariah8.0% MSCI Islamic11.9% MSCI Islamic M-Series8.0% FTSE Shariah0.0% |
| MNKD MannKind Corp. | NON_COMPLIANT | 0.06% | AAOIFI26.0% Usmani45.2% Dow Jones Islamic22.7% S&P Shariah24.3% MSCI Islamic45.2% MSCI Islamic M-Series24.3% FTSE Shariah43.6% |
| EYPT EyePoint, Inc. | NON_COMPLIANT | 0.06% | AAOIFIfail Usmanifail Dow Jones Islamicpass S&P Shariahpass MSCI Islamicfail MSCI Islamic M-Seriespass FTSE Shariahfail |
| ALVO Alvotech SA | NON_COMPLIANT | 0.06% | AAOIFI61.2% Usmani87.4% Dow Jones Islamic56.2% S&P Shariah50.1% MSCI Islamic87.4% MSCI Islamic M-Series50.1% FTSE Shariah87.4% |
| COLL Collegium Pharmaceutical, Inc. | NON_COMPLIANT | 0.05% | AAOIFI31.8% Usmani11.4% Dow Jones Islamic21.9% S&P Shariah22.5% MSCI Islamic11.4% MSCI Islamic M-Series22.5% FTSE Shariah11.2% |
| SVRA Savara, Inc. | NON_COMPLIANT | 0.05% | AAOIFI2.7% Usmani15.7% Dow Jones Islamic3.9% S&P Shariah4.2% MSCI Islamic15.7% MSCI Islamic M-Series4.2% FTSE Shariah15.7% |
| OLMA Olema Pharmaceuticals, Inc. | NON_COMPLIANT | 0.05% | AAOIFI0.1% Usmani0.1% Dow Jones Islamic0.1% S&P Shariah0.1% MSCI Islamic0.1% MSCI Islamic M-Series0.1% FTSE Shariah0.0% |
| CRVS Corvus Pharmaceuticals, Inc. | COMPLIANT | 0.05% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| XERS Xeris Biopharma Holdings, Inc. | COMPLIANT | 0.05% | AAOIFI19.9% Usmani70.3% Dow Jones Islamic30.4% S&P Shariah39.2% MSCI Islamic70.3% MSCI Islamic M-Series39.2% FTSE Shariah61.3% |
| ABSI Absci Corp. | COMPLIANT | 0.05% | AAOIFI— Usmanifail Dow Jones Islamicfail S&P Shariah— MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| ZBIO Zenas Biopharma, Inc. | NON_COMPLIANT | 0.05% | AAOIFI3.9% Usmani11.3% Dow Jones Islamic8.0% S&P Shariah— MSCI Islamic11.3% MSCI Islamic M-Series— FTSE Shariah11.2% |
| Cullinan Therapeutics, Inc. | UNSCREENED | 0.05% | no in-house ratios for this holding |
| GRF.MC Grifols SA | NON_COMPLIANT | 0.05% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariahfail MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| PCRX Pacira BioSciences, Inc. | NON_COMPLIANT | 0.05% | AAOIFI39.2% Usmani33.1% Dow Jones Islamic41.2% S&P Shariah37.5% MSCI Islamic33.1% MSCI Islamic M-Series37.5% FTSE Shariah29.2% |
| SPRY ARS Pharmaceuticals, Inc. | NON_COMPLIANT | 0.05% | AAOIFI17.3% Usmani38.7% Dow Jones Islamic8.7% S&P Shariah9.8% MSCI Islamic38.7% MSCI Islamic M-Series9.8% FTSE Shariah38.7% |
| JANX Janux Therapeutics, Inc. | NON_COMPLIANT | 0.04% | AAOIFI1.7% Usmani2.1% Dow Jones Islamic1.4% S&P Shariah1.4% MSCI Islamic2.1% MSCI Islamic M-Series1.4% FTSE Shariah0.0% |
| Kura Oncology, Inc. | UNSCREENED | 0.04% | no in-house ratios for this holding |
| Sana Biotechnology, Inc. | UNSCREENED | 0.04% | no in-house ratios for this holding |
| ABUS Arbutus Biopharma Corp. | NON_COMPLIANT | 0.04% | AAOIFI0.1% Usmani0.2% Dow Jones Islamic0.1% S&P Shariah0.1% MSCI Islamic0.2% MSCI Islamic M-Series0.1% FTSE Shariah0.0% |
| Xencor, Inc. | UNSCREENED | 0.04% | no in-house ratios for this holding |
| MGTX MeiraGTx Holdings plc | COMPLIANT | 0.04% | AAOIFI0.9% Usmani3.1% Dow Jones Islamic1.9% S&P Shariah2.2% MSCI Islamic3.1% MSCI Islamic M-Series2.2% FTSE Shariah0.0% |
| Amphastar Pharmaceuticals, Inc. | UNSCREENED | 0.04% | no in-house ratios for this holding |
| ORIC ORIC Pharmaceuticals, Inc. | COMPLIANT | 0.04% | AAOIFI0.3% Usmani0.8% Dow Jones Islamic0.4% S&P Shariah0.4% MSCI Islamic0.8% MSCI Islamic M-Series0.4% FTSE Shariah0.0% |
| ETON Eton Pharmaceuticals, Inc. | COMPLIANT | 0.04% | AAOIFI1.7% Usmani25.2% Dow Jones Islamic5.4% S&P Shariah7.4% MSCI Islamic25.2% MSCI Islamic M-Series7.4% FTSE Shariah24.1% |
| Theravance Biopharma, Inc. | UNSCREENED | 0.04% | no in-house ratios for this holding |
| MESO Mesoblast Ltd. | COMPLIANT | 0.04% | AAOIFI4.1% Usmani16.2% Dow Jones Islamic0.7% S&P Shariah1.0% MSCI Islamic16.2% MSCI Islamic M-Series1.0% FTSE Shariah16.2% |
| Geron Corp. | UNSCREENED | 0.04% | no in-house ratios for this holding |
| ANNX Annexon, Inc. | COMPLIANT | 0.04% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| Omeros Corp. | UNSCREENED | 0.04% | no in-house ratios for this holding |
| PHAT Phathom Pharmaceuticals, Inc. | NON_COMPLIANT | 0.04% | AAOIFI55.2% Usmani123.6% Dow Jones Islamic53.0% S&P Shariah57.8% MSCI Islamic123.6% MSCI Islamic M-Series57.8% FTSE Shariah122.8% |
| BIOA BioAge Labs, Inc. | NON_COMPLIANT | 0.04% | AAOIFI0.6% Usmani0.7% Dow Jones Islamic0.6% S&P Shariah— MSCI Islamic0.7% MSCI Islamic M-Series— FTSE Shariah0.0% |
| Esperion Therapeutics, Inc. | UNSCREENED | 0.04% | no in-house ratios for this holding |
| Replimune Group, Inc. | UNSCREENED | 0.04% | no in-house ratios for this holding |
| MRVI Maravai LifeSciences Holdings, Inc. | NON_COMPLIANT | 0.04% | AAOIFI7.7% Usmani29.3% Dow Jones Islamic13.5% S&P Shariah10.6% MSCI Islamic24.4% MSCI Islamic M-Series10.6% FTSE Shariah24.4% |
| CorMedix, Inc. | UNSCREENED | 0.03% | no in-house ratios for this holding |
| Zevra Therapeutics, Inc. | UNSCREENED | 0.03% | no in-house ratios for this holding |
| PRME Prime Medicine, Inc. | NON_COMPLIANT | 0.03% | AAOIFI16.8% Usmani45.2% Dow Jones Islamic21.9% S&P Shariah18.8% MSCI Islamic45.2% MSCI Islamic M-Series18.8% FTSE Shariah0.0% |
| PAHC Phibro Animal Health Corp. | NON_COMPLIANT | 0.03% | AAOIFI43.6% Usmani45.1% Dow Jones Islamic51.7% S&P Shariah64.2% MSCI Islamic45.1% MSCI Islamic M-Series64.2% FTSE Shariah41.3% |
| CSTL Castle Biosciences, Inc. | NON_COMPLIANT | 0.03% | AAOIFI3.3% Usmani6.5% Dow Jones Islamic4.7% S&P Shariah5.1% MSCI Islamic6.5% MSCI Islamic M-Series5.1% FTSE Shariah1.8% |
| VOR Vor BioPharma, Inc. | NON_COMPLIANT | 0.03% | AAOIFI0.3% Usmani0.6% Dow Jones Islamic0.9% S&P Shariah1.2% MSCI Islamic0.6% MSCI Islamic M-Series1.2% FTSE Shariah0.0% |
| CTMX CytomX Therapeutics, Inc. | NON_COMPLIANT | 0.03% | AAOIFI0.7% Usmani1.5% Dow Jones Islamic1.3% S&P Shariah1.8% MSCI Islamic1.5% MSCI Islamic M-Series1.8% FTSE Shariah0.0% |
| Candel Therapeutics, Inc. | UNSCREENED | 0.03% | no in-house ratios for this holding |
| 9688.HK Zai Lab Ltd. | NON_COMPLIANT | 0.03% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariahfail MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| Design Therapeutics, Inc. | UNSCREENED | 0.03% | no in-house ratios for this holding |
| TECX Tectonic Therapeutic, Inc. | NON_COMPLIANT | 0.03% | AAOIFI0.7% Usmani1.9% Dow Jones Islamic0.9% S&P Shariah1.2% MSCI Islamic1.8% MSCI Islamic M-Series1.2% FTSE Shariah0.0% |
| IRWD Ironwood Pharmaceuticals, Inc. | NON_COMPLIANT | 0.03% | AAOIFI30.0% Usmani74.1% Dow Jones Islamic45.1% S&P Shariah27.1% MSCI Islamic74.1% MSCI Islamic M-Series27.1% FTSE Shariah70.0% |
| Arvinas, Inc. | UNSCREENED | 0.03% | no in-house ratios for this holding |
| Solid Biosciences, Inc. | UNSCREENED | 0.03% | no in-house ratios for this holding |
| RIGL Rigel Pharmaceuticals, Inc. | COMPLIANT | 0.03% | AAOIFI5.0% Usmani8.8% Dow Jones Islamic9.0% S&P Shariah11.3% MSCI Islamic8.8% MSCI Islamic M-Series11.3% FTSE Shariah8.6% |
| ACRS Aclaris Therapeutics, Inc. | NON_COMPLIANT | 0.03% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariahfail MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| PRTA Prothena Corp. plc | NON_COMPLIANT | 0.03% | AAOIFI1.4% Usmani2.3% Dow Jones Islamic1.2% S&P Shariah0.8% MSCI Islamic2.3% MSCI Islamic M-Series0.8% FTSE Shariah0.0% |
| FDMT 4D Molecular Therapeutics, Inc. | NON_COMPLIANT | 0.03% | AAOIFI4.7% Usmani8.0% Dow Jones Islamic9.8% S&P Shariah6.8% MSCI Islamic8.0% MSCI Islamic M-Series6.8% FTSE Shariah4.0% |
| AQST Aquestive Therapeutics, Inc. | COMPLIANT | 0.02% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| Allogene Therapeutics, Inc. | UNSCREENED | 0.02% | no in-house ratios for this holding |
| KYTX Kyverna Therapeutics, Inc. | NON_COMPLIANT | 0.02% | AAOIFI6.4% Usmani15.0% Dow Jones Islamic11.3% S&P Shariah8.6% MSCI Islamic15.0% MSCI Islamic M-Series8.6% FTSE Shariah11.3% |
| Aura Biosciences, Inc. | UNSCREENED | 0.02% | no in-house ratios for this holding |
| Fulcrum Therapeutics, Inc. | UNSCREENED | 0.02% | no in-house ratios for this holding |
| UPB Upstream Bio, Inc. | NON_COMPLIANT | 0.02% | AAOIFI0.3% Usmani0.3% Dow Jones Islamic0.1% S&P Shariah— MSCI Islamic0.3% MSCI Islamic M-Series— FTSE Shariah0.0% |
| Kamada Ltd. | UNSCREENED | 0.02% | no in-house ratios for this holding |
| PACB Pacific Biosciences of California, Inc. | NON_COMPLIANT | 0.02% | AAOIFI168.3% Usmani93.9% Dow Jones Islamic143.6% S&P Shariah79.6% MSCI Islamic93.9% MSCI Islamic M-Series79.6% FTSE Shariah85.7% |
| First Tracks Biotherapeutics, Inc. | UNSCREENED | 0.02% | no in-house ratios for this holding |
| NGNE Neurogene, Inc. | NON_COMPLIANT | 0.02% | AAOIFI1.1% Usmani3.4% Dow Jones Islamic2.2% S&P Shariah2.5% MSCI Islamic3.4% MSCI Islamic M-Series2.5% FTSE Shariah0.0% |
| C4 Therapeutics, Inc. | UNSCREENED | 0.02% | no in-house ratios for this holding |
| EOLS Evolus, Inc. | NON_COMPLIANT | 0.02% | AAOIFI33.8% Usmani66.4% Dow Jones Islamic29.3% S&P Shariah26.8% MSCI Islamic66.4% MSCI Islamic M-Series26.8% FTSE Shariah63.2% |
| LKFT.AS Lakefront Biotherapeutics NV | NON_COMPLIANT | 0.02% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariahfail MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| CTNM Contineum Therapeutics, Inc. | NON_COMPLIANT | 0.02% | AAOIFI1.0% Usmani2.6% Dow Jones Islamic2.5% S&P Shariah2.4% MSCI Islamic2.6% MSCI Islamic M-Series2.4% FTSE Shariah0.0% |
| OABI OmniAb, Inc. | NON_COMPLIANT | 0.02% | AAOIFI3.0% Usmani6.5% Dow Jones Islamic5.9% S&P Shariah4.7% MSCI Islamic6.5% MSCI Islamic M-Series4.7% FTSE Shariah0.0% |
| Altimmune, Inc. | UNSCREENED | 0.02% | no in-house ratios for this holding |
| Enanta Pharmaceuticals, Inc. | UNSCREENED | 0.02% | no in-house ratios for this holding |
| VNDA Vanda Pharmaceuticals, Inc. | NON_COMPLIANT | 0.02% | AAOIFI5.1% Usmani5.5% Dow Jones Islamic4.9% S&P Shariah5.2% MSCI Islamic3.8% MSCI Islamic M-Series5.2% FTSE Shariah0.0% |
| Larimar Therapeutics, Inc. | UNSCREENED | 0.02% | no in-house ratios for this holding |
| 6A3A.SG Autolus Therapeutics plc | NON_COMPLIANT | 0.02% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariahfail MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| Lexeo Therapeutics, Inc. | UNSCREENED | 0.02% | no in-house ratios for this holding |
| Immuneering Corp. | UNSCREENED | 0.02% | no in-house ratios for this holding |
| LYEL Lyell Immunopharma, Inc. | NON_COMPLIANT | 0.02% | AAOIFI14.1% Usmani15.0% Dow Jones Islamic14.9% S&P Shariah12.4% MSCI Islamic15.0% MSCI Islamic M-Series12.4% FTSE Shariah0.0% |
| Atea Pharmaceuticals, Inc. | UNSCREENED | 0.02% | no in-house ratios for this holding |
| Puma Biotechnology, Inc. | UNSCREENED | 0.02% | no in-house ratios for this holding |
| Cabaletta Bio, Inc. | UNSCREENED | 0.02% | no in-house ratios for this holding |
| RGNX REGENXBIO, Inc. | NON_COMPLIANT | 0.02% | AAOIFI11.7% Usmani17.8% Dow Jones Islamic14.0% S&P Shariah12.0% MSCI Islamic17.8% MSCI Islamic M-Series12.0% FTSE Shariah0.0% |
| KROS Keros Therapeutics, Inc. | NON_COMPLIANT | 0.02% | AAOIFI7.4% Usmani5.5% Dow Jones Islamic3.8% S&P Shariah2.7% MSCI Islamic5.5% MSCI Islamic M-Series2.7% FTSE Shariah0.0% |
| EDIT Editas Medicine, Inc. | NON_COMPLIANT | 0.02% | AAOIFI14.4% Usmani30.0% Dow Jones Islamic30.8% S&P Shariah20.4% MSCI Islamic30.0% MSCI Islamic M-Series20.4% FTSE Shariah23.5% |
| SIGA SIGA Technologies, Inc. | NON_COMPLIANT | 0.02% | AAOIFI0.2% Usmani0.3% Dow Jones Islamic0.1% S&P Shariah0.1% MSCI Islamic0.3% MSCI Islamic M-Series0.1% FTSE Shariah0.0% |
| RCKT Rocket Pharmaceuticals, Inc. | NON_COMPLIANT | 0.02% | AAOIFI0.8% Usmani5.9% Dow Jones Islamic0.5% S&P Shariah0.3% MSCI Islamic0.8% MSCI Islamic M-Series0.3% FTSE Shariah0.0% |
| SLN Silence Therapeutics plc | NON_COMPLIANT | 0.02% | AAOIFI0.0% Usmani0.1% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.1% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| Invivyd, Inc. | UNSCREENED | 0.02% | no in-house ratios for this holding |
| Neumora Therapeutics, Inc. | UNSCREENED | 0.02% | no in-house ratios for this holding |
| TKNO Alpha Teknova, Inc. | COMPLIANT | 0.01% | AAOIFI7.3% Usmani28.6% Dow Jones Islamic9.7% S&P Shariah12.3% MSCI Islamic28.6% MSCI Islamic M-Series12.3% FTSE Shariah13.8% |
| Anavex Life Sciences Corp. | UNSCREENED | 0.01% | no in-house ratios for this holding |
| TRDA Entrada Therapeutics, Inc. | NON_COMPLIANT | 0.01% | AAOIFI17.5% Usmani16.2% Dow Jones Islamic12.3% S&P Shariah11.3% MSCI Islamic16.2% MSCI Islamic M-Series11.3% FTSE Shariah0.0% |
| ACIU AC Immune SA | NON_COMPLIANT | 0.01% | AAOIFIfail Usmanifail Dow Jones Islamicfail S&P Shariah— MSCI Islamicfail MSCI Islamic M-Seriesfail FTSE Shariahfail |
| HUMA Humacyte, Inc. | NON_COMPLIANT | 0.01% | AAOIFI21.6% Usmani47.9% Dow Jones Islamic11.0% S&P Shariah9.5% MSCI Islamic26.3% MSCI Islamic M-Series9.5% FTSE Shariah26.3% |
| FHTX Foghorn Therapeutics, Inc. | NON_COMPLIANT | 0.01% | AAOIFI14.8% Usmani21.2% Dow Jones Islamic14.3% S&P Shariah15.2% MSCI Islamic21.2% MSCI Islamic M-Series15.2% FTSE Shariah0.0% |
| Codexis, Inc. | UNSCREENED | 0.01% | no in-house ratios for this holding |
| LENZ LENZ Therapeutics, Inc. | NON_COMPLIANT | 0.01% | AAOIFI0.3% Usmani0.2% Dow Jones Islamic0.1% S&P Shariah0.1% MSCI Islamic0.2% MSCI Islamic M-Series0.1% FTSE Shariah0.0% |
| Coherus Oncology, Inc. | UNSCREENED | 0.01% | no in-house ratios for this holding |
| Quantum-Si, Inc. | UNSCREENED | 0.01% | no in-house ratios for this holding |
| VYGR Voyager Therapeutics, Inc. | NON_COMPLIANT | 0.01% | AAOIFI17.2% Usmani16.5% Dow Jones Islamic13.5% S&P Shariah11.1% MSCI Islamic16.5% MSCI Islamic M-Series11.1% FTSE Shariah0.0% |
The published standards disagree about this fund by 15 points of portfolio weight — 20.3% of it passes AAOIFI, 4.9% passes MSCI Islamic. Which number is yours depends on which standard you follow.
These bars are the financial-ratio result under each standard — debt, receivables and interest income. They do not screen what the business does, so a holding can pass every ratio here and still be questionable or non-compliant on activity. The blended verdict above accounts for both.
ratios pass on 20.3% ratios fail on 12.7% 61.5% not rated under AAOIFI
ratios pass on 6.8% ratios fail on 23.3% 64.4% not rated under Usmani
ratios pass on 17.3% ratios fail on 14.5% 62.7% not rated under Dow Jones Islamic
ratios pass on 17.4% ratios fail on 14.0% 63.1% not rated under S&P Shariah
ratios pass on 4.9% ratios fail on 30.7% 58.9% not rated under MSCI Islamic
ratios pass on 17.4% ratios fail on 14.2% 63.0% not rated under MSCI Islamic M-Series
ratios pass on 6.9% ratios fail on 23.2% 64.4% not rated under FTSE Shariah
162 of 267 listed holdings carry our own per-methodology verdicts (49% of weight). The rest hold a provider verdict with no methodology breakdown, and are counted as rated by none. Of those, 130 (36% of weight) also carry the underlying debt ratio; the rest show a verdict without the figure behind it.
| Non-compliant holding | Weight |
|---|---|
| UTHR United Therapeutics Corp. | 1.22% |
| RPRX Royalty Pharma plc | 1.20% |
| VTRS Viatris, Inc. | 0.94% |
| MRNA Moderna, Inc. | 0.94% |
| IONS Ionis Pharmaceuticals, Inc. | 0.63% |
| BMRN BioMarin Pharmaceutical, Inc. | 0.55% |
| 22UA.DE BioNTech SE | 0.55% |
| CYTK Cytokinetics, Inc. | 0.47% |
| KRYS Krystal Biotech, Inc. | 0.45% |
| KYMR Kymera Therapeutics, Inc. | 0.33% |
Methodology breakdown computing — it will appear here on its own.
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
ProShares Ultra Nasdaq Biotechnology (BIB) is currently considered not halal (non-compliant), per our own look-through to its filed holdings. See its filed holdings and the weight breakdown below for the reasoning.
Computing the full ratio and business-activity breakdown for BIB — this runs off the critical path so the page paints first. It will appear here on its own.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 42.50 | NEUTRAL |
| Stochastic %K (14) | 30.36 | NEUTRAL |
| CCI (20) | -133.09 | BUY |
| Williams %R (14) | -69.64 | NEUTRAL |
| MACD (12,26,9) | -0.68 | SELL |
| ROC (10) | -8.55 | SELL |
| Momentum (10) | -9.91 | SELL |
| EMA (10) | 109.16 | SELL |
| SMA (10) | 109.29 | SELL |
| EMA (20) | 110.69 | SELL |
| SMA (20) | 111.46 | SELL |
| EMA (30) | 111.09 | SELL |
| SMA (30) | 112.60 | SELL |
| EMA (50) | 109.86 | SELL |
| SMA (50) | 112.89 | SELL |
| EMA (100) | 104.19 | BUY |
| SMA (100) | 102.67 | BUY |
| EMA (200) | 94.91 | BUY |
| SMA (200) | 92.78 | BUY |
The index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies. Under normal circumstances, the fund will obtain leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.
Background via Yahoo Finance — informational, not part of the verdict.
Average — needs more confirmation before sizing up
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 42 |
| 🕐 1H | BEARISH | 22 |
| ⏱ 15-Min | RANGING | 88 |
| ⏲ 5-Min | BEARISH | 234 |
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
The questions worth asking about any verdict on this page, answered plainly.
No. HTR reads the fund's filed holdings and screens each one, then reports the result by weight. A fund marketed as Islamic still gets the same look-through as any other.
It is the share of the fund whose holdings HTR cannot cover far enough to rate. It is reported as unrated rather than counted as compliant, because a holding nobody screened should not look like one that passed.
It matters, and it is noted, but it does not replace the look-through. The board's judgement and the holdings screen are shown separately so you can see when they agree and when they do not.
When the fund files new holdings, and on a rolling basis besides. The date on the verdict above is the last time this fund was actually recomputed.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
NO DATA 0 buys · 0 sells
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-10-06 · Asset managers net 906615 (+2612)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.